Immune responses to gene-modified T cells

Current Gene Therapy

Volumn 7, Issue 5, 2007, Pages 361-368

  Muul, Linda M ^a   Candotti, Fabio ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; CASPASE 9; ENHANCED GREEN FLUORESCENT PROTEIN; FK 506 BINDING PROTEIN; GREEN FLUORESCENT PROTEIN; HYGROMYCIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KANAMYCIN KINASE; MACROGOL; NERVE GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE; RETROVIRUS VECTOR; THYMIDINE KINASE; YELLOW FLUORESCENT PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY RESPONSE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CULTURE MEDIUM; CYTOTOXICITY; DISEASE SEVERITY; DNA MODIFICATION; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GRAFT VERSUS HOST REACTION; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LEUKEMIA; LYMPHOCYTE CULTURE; LYMPHOCYTE TRANSFER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATIENT SAFETY; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE; TRANSGENE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODY FORMATION; CELL CULTURE TECHNIQUES; CHILD; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HOST VS GRAFT REACTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; METABOLIC DISEASES; MICE; NEOPLASMS; T-LYMPHOCYTES; TISSUE THERAPY; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 35348960011     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652307782151489     Document Type: Review

References (75)

1. Arthur, L. O., Bess, J.W., Jr., Sowder, R. C., 2nd, Benveniste, R. E., Mann, D. L., Chermann, J. C. and Henderson, L. E. (1992). Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science, 258: 1935-1938.
2. Beagles, K. E., Peterson, L., Zhang, X., Morris, J. and Kiem, H. P. (2005). Cyclosporine inhibits the development of green fluorescent protein (GFP)-specific immune responses after transplantation of GFP-expressing hematopoietic repopulating cells in dogs. Hum. Gene Ther., 16: 725-733.
3. Berger, C., Blau, C. A., Huang, M. L., Iuliucci, J. D., Dalgarno, D. C., Gaschet, J., Heimfeld, S., Clackson, T. and Riddell, S. R. (2004). Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood, 103: 1261-1269.
4. Berger, C., Flowers, M. E., Warren, E. H. and Riddell, S. R. (2006). Analysis of transgene-specific immune responses that limit the in. vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood, 107: 2294-2302.
5. Blaese, R. M., Culver, K. W., Miller,, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., Greenblatt, J. J., Rosenberg, S. A., Klein, H., Berger, M., Mullen, C. A., Ramsey, W. J., Muul, L., Morgan, R. A. and Anderson, W. F. (1995). T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science, 270: 475-480.
6. Bonini, C., Bondanza, A., Perna, S. K., Kaneko, S., Traversari, C., Ciceri, F. and Bordignon, C. (2007). The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol. Ther., 15: 1248-1252.
7. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. and Bordignon, C. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276: 1719-1724.
8. Bonini, C., Grez, M., Traversari, C., Ciceri, F., Marktel, S., Ferrari, G., Dinauer, M., Sadat, M., Aiuti, A., Deola, S., Radrizzani, M., Hagenbeek, A., Apperley, J., Ebeling, S., Martens, A., Kolb, H. J., Weber, M., Lotti, F., Grande, A., Weissinger, E., Bueren, J. A., Lamana, M., Falkenburg, J. H., Heemskerk, M. H., Austin, T., Kornblau, S., Marini, F., Benati, C., Magnani, Z., Cazzaniga, S., Toma, S., Gallo-Stampino, C., Introna, M., Slavin, S., Greenberg, P. D., Bregni, M., Mavilio, F. and Bordignon, C. (2003). Safety of retroviral gene marking with a truncated NGF receptor. Nat. Med., 9:367-369.
9. Bordignon, C., Notarangelo, L. D., Nobili, N., Ferrari, G., Casorati, G., Panina, P., Mazzolari, E., Maggioni, D., Rossi, C., Servida, P., Ugazio, A. G. and Mavilio, F. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science, 270: 470-475.
10. Borrelli, E., Heyman, R., Hsi, M. and Evans, R. M. (1988). Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. USA, 85: 7572-7576.
11. Buckley, R. H., Schiff, S. E., Sampson, H. A., Schiff, R. I., Markert, M. L., Knutsen, A. P., Hershfield, M. S., Huang, A. T., Mickey, G. H. and Ward, F. E. (1986). Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J. Immunol., 136: 2398-2407.
12. Bunnell, B. A., Metzger, M., Byrne, E., Morgan, R. A. and Donahue, R. E. (1997). Efficient in vivo marking of primary CD4+ T lymphocytes in nonhuman primates using a gibbon ape leukemia virus-derived retroviral vector. Blood, 89: 1987-1995.
13. Burt, R. K., Drobyski, W. R., Seregina, T., Traynor, A., Oyama, Y., Keever-Taylor, C., Stefka, J., Kuzel, T. M., Brush, M., Rodriquez, J., Burns, W., Tennant, L. and Link, C. (2003). Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp. Hematol, 31: 903-910.
14. Candotti, F., Agbaria, R., Mullen, C. A., Touraine, R., Balzarini, J., Johns, D. G. and Blaese, R. M. (2000). Use of a herpes thymidine kinase/ neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer. Cancer Gene Ther., 7: 574-580.
15. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W. and Prasher, D. C. (1994). Green fluorescent protein as a marker for gene expression. Science, 263: 802-805.
16. Ciceri, F., Bonini, C., Marktel, S., Zappone, E., Servida, P., Bernardi, M., Pescarollo, A., Bondanza, A., Peccatori, J., Rossini, S., Magnani, Z., Salomoni, M., Benati, C., Ponzoni, M., Callegaro, L., Corradini, P., Bregni, M., Traversari, C. and Bordignon, C. (2007). Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood, 109: 4698-4707.
17. Clackson, T., Yang, W., Rozamus, L. W., Hatada, M., Amara, J. F., Rollins, C. T., Stevenson, L. F., Magari, S. R., Wood, S. A., Courage, N. L., Lu, X., Cerasoli, F., Jr., Gilman, M. and Holt, D. A. (1998). Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. USA, 95: 10437-10442.
18. Culver, K. W. anderson, W. F. and Blaese, R. M. (1991). Lymphocyte gene therapy. Hum. Gene Ther., 2: 107-109.
19. Dotti, G. and Heslop, H. E. (2005). Current status of genetic modification of T cells for cancer treatment. Cytotheraphy 7: 262-272.
20. Dropulic, B. and June, C. H. (2006). Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum. Gene Ther., 17: 577-588.
21. Fehse, B., Ayuk, F. A., Kroger, N., Fang, L., Kuhlcke, K., Heinzelmann, M., Zabelina, T., Fauser, A. A. and Zander, A. R. (2004). Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood, 104: 3408-3409.
22. Felise, B., Richters, A., Putimtseva-Scharf, K., Klump, H., Li, Z., Ostertag, W., Zander, A. R. and Baum, C. (2000). CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol. Ther., 1: 448-456.
23. Ferrari, G., Rossini, S., Giavazzi, R., Maggioni, D., Nobili, N., Soldati, M., Urgers, G., Mavilio, F., Gilboa, E. and Bordignon, C. (1991). An in. vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science, 251: 1363-1366.
24. Flugel, A., Willem, M., Berkowicz, T. and Wekerle, H. (1999). Gene transfer into CD4+ T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat. Med, 5: 843-847.
25. Hammer, M. H., Flugel, A., Seifert, M., Lehmann, M., Brandt, C., Volk, H. D. and Ritter, T. (2000). Potential of allospecific gene-engineered T cells in transplantation gene therapy: specific T cell activation determines transgene expression in vitro and in vivo. Hum. Gene Ther., 11: 1303-1311.
26. Heim, D. A., Hanazono, Y., Giri, N., Wu, T., Childs, R., Sellers, S. E., Muul, L., Agricola, B. A., Metzger, M. E., Donahue, R. E., Tisdale, J. F. and Dunbar, C. E. (2000). Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol. Ther., 1: 533-544.
27. Hershfield, M. S., Buckley, R. H., Greenberg, M. L., Melton, A. L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M. L., Kobayashi, R. H., Kobayashi, A. L. and Abuchowski, A. (1987). Treatment of adenosine deaminase. deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med., 316: 589-596.
28. Horowitz, M. M., Gale, R. P., Sondel, P. M., Goldman, J. M., Kersey, J., Kolb, H. J., Rimm, A. A., Ringden, O., Rozman, C., Speck, B. and Bortin, M. M. (1990). Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75: 555-562.
29. Junker, K., Koehl, U., Zimmerman, S., Stein, S., Schwabe, D., Klingebiel, T. and Grez, M. (2003). Kinetics of cell death in T'lymphocytes genetically modified with two novel suicide fusion genes. Gene Ther., 10: 1189-1197.
30. Kantoff, P. W., Kohn, D. B., Mitsuya, H., Armentano, D., Sieberg, M., Zwiebel, J. A., Eglitis, M. A., Mclachlin, J. R., Wiginton, D. A., Hutton, J. J. and Horowitz, S. D., Gilboa, E., Blaese, R. M. and Anderson, W. F. (1986). Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA, 83: 6563-6567.
31. Kershaw, M. H., Teng, M. W., Smyth, M. J. and Darcy, P. K. (2005) Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol., 5:928-940.
32. Krause, D. S., Fackler, M. J., Civin, C. I. and May, W. S. (1996). CD34: structure, biology, and clinical utility. Blood, 87: 1-13.
33. Kyttaris, V. C., Sfikakis, P. P., Juang, Y. T. and Tsokos, G. C. (2005). Gene therapy in systemic lupus erythematosus. Curr. Gene Ther., 5: 677-684.
34. Leen, A. M., Rooney, C. M. and Foster, A. E. (2007). Improving T cell therapy for cancer. Annu. Rev. Immunol., 25: 243-265.
35. Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., Von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H. G., Fehse, B. and Baum, C. (2002). Murine leukemia induced by retroviral gene marking. Science, 296: 497.
36. Liberatore, C., Capanni, M., Albi, N., Volpi, I., Urbani, E., Ruggeri, L., Mencarelli, A., Grignani, F. and Velardi, A. (1999). Natural killer cell-mediated lysis of autologous cells modified by gene therapy. J. Exp. Med., 189: 1855-1962.
37. Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H., Reich, L., Collins, N. H., Boulad, F., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., Kernan, N. A. and Small, T. N., Young, J. W. and O'Reilly, R. J. (1995). Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86: 1261-1268.
38. Mansoor, W., Gilham, D. E., Thistlethwaite, F. C. and Hawkins, R. E. (2005). Engineering T cells for cancer therapy. Br. J. Cancer, 93: 1085-1091.
39. Mavilio, F., Ferrari, G., Rossini, S., Nobili, N., Bonini, C., Casorati, G., Traversari, C. and Bordignon, C. (1994). Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood, 83: 1988-1997.
40. Mccormack, J. E., Martineau, D., Depolo, N., Maifert, S., Akbarian, L., Townsend, K., Lee, W., Irwin, M., Sajjadi, N., Jolly, D. J. and Warner, J. (1997). Anti-vector immunoglobulin induced by retroviral vectors. Hum. Gene Ther., 8: 1263-1273.
41. Moolten, F. L. and Wells, J. M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst., 82: 297-300.
42. Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., Zheng, Z., Nahvi, A., De Vries, C. R., Rogers-Freezer, L. J., Mavroukakis, S. A. and Rosenberg, S. A. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314: 126-129.
43. Morris, J. C., Conerly, M., Thomasson, B., Storek, J., Riddell, S. R. and Kiem, H. P. (2004). Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood, 103: 492-499.
44. Muul, L. M., Tuschong, L. M., Soenen, S. L., Jagadeesh, G. J., Ramsey, W. J., Long, Z., Carter, C. S., Garabedian, E. K., Alleyne, M., Brown, M., Bernstein, W., Schurman, S. H., Fleisher, T. A., Leitman, S. F., Dunbar, C. E., Blaese, R. M. and Candotti, F. (2003). Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood, 101: 2563-2569.
45. Nakajima, A. (2006). Application of cellular gene therapy for rheumatoid arthritis. Mod. Rheumatol., 16: 269-275.
46. Ossevoort, M., Zaldumbide, A., Cramer, S. J., Van Der Voort, E. I., Toes, R. E. and Hoeben, R. C. (2006). Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinase. Gene Cancer Gene Ther., 13: 584-591.
47. Palmer, D. H., Young, L. S. and Mautner, V. (2006). Cancer gene-therapy: clinical trials. Trends Biotechnol., 24: 76-82.
48. Papadimitriou, C. A., Roots, A., Koenigsmann, M., Koenigsmann, M., Mucke, C., Oelmann, E., Oberberg, D., Reufi, B., Thiel, E. and Berdel, W. E. (1995). Immunomagnetic selection of CD34+ cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques. J. Hematother., 4: 539-544.
49. Phillips, K., Gentry, T., Mccowage, G., Gilboa, E. and Smith, C. (1996). Cell-surface markers for assessing gene transfer into human hematopoietic cells. Nat. Med., 2: 1154-1156.
50. Portsmouth, D., Hlavaty, J. and Renner, M. (2007). Suicide genes for cancer therapy. Mol. Aspects. Med., 28: 4-41.
51. Qasim, W., Gaspar, H. B. and Thrasher, A. J. (2005). T cell suicide gene therapy to aid haematopoietic stem cell transplantation. Curr. Gene Ther., 5: 121-132.
52. Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., Devroom, H. L., Otto, E., Long, Z., Chiang, Y., Mcgarrity, G. J., Muul, L. M., Katz, D., Blaese, R. M. and Oldfield, E. H. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 3: 1354-1361.
53. Rettig, M. P., Ritchey, J. K., Meyerrose, T. E., Haug, J. S. and Dipersio, J. F. (2003). Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol. Ther., 8: 29-41.
54. Riddell, S. R., Elliott M., Lewinsohn, D. A., Gilbert, M. J., Wilson, L., Manley, S. A., Lupton, S. D., Overell, R. W., Reynolds, T. C., Corey, L. and Greenberg, P. D. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med., 2: 216-223.
55. Riddell, S. R. and Greenberg, P. D. (1995). Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol., 13: 545-586.
56. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E. and Greenberg, P. D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science, 257: 238-241.
57. Robinet, E., Fehse, B., Ebeling, S., Sauce, D., Ferrand, C. and Tiberghien, P. (2005). Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function. Cytotherapy, 7: 150-157.
58. Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L. and et. al. (1990). Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med., 323: 570-578.
59. Sakamoto, N., Tsuji, K., Muul, L. M., Lawler, A. M., Petricoin, E. F., Candotti, F., Metcalf, J. A., Tavel, J. A., Lane, H. C., Urba, W. J., Fox, B. A., Varki, A., Lunney, J. K. and Rosenberg, A. S. (2007). Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood, 110: 501-508.
60. Selvaggi, T. A., Walker, R. E. and Fleisher, T. A. (1997). Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood, 89: 776-779.
61. Spencer, D. M., Belshaw, P. J., Chen, L., Ho, S. N., Randazzo, F., Crabtree, G. R. and Schreiber, S. L. (1996). Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr. Biol., 6: 839-847.
62. Straathof, K. C., Pule, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M. and Rooney, C. M. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood, 105: 4247-4254.
63. Stripecke, R., Carmen Villacres, M., Skelton, D., Satake, N., Halene, S. and Kohn, D. (1999). Immune response to green fluorescent protein: implications for gene therapy. Gene Ther., 6: 1305-1312.
64. Suomalainen, M. and Garoff, H. (1994). Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus. J. Virol., 68: 4879-4889.
65. Tarner, I. H., Neumann, E., Gay, S., Fathman, C. G. and Muller-Ladner, U. (2006). Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Autoimmun. Rev., 5: 148-152.
66. Thomis, D. C., Marktel, S., Bonini, C., Traversari, C., Gilman, M., Bordignon, C. and Clackson, T. (2001). A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood, 97: 1249-1257.
67. Tiberghien, P., Ferrand, C., Lioure, B., Milpied, N., Angonin, R., Deconinck, E., Certoux, J. M., Robinet, E., Saas, P., Petracca, B., Juttner, C., Reynolds, C. W., Longo, D. L., Herve, P. and Cahn, J. Y. (2001). Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood, 97: 63-72.
68. Tiberghien, P., Reynolds, C. W., Keller, J., Spence, S., Deschaseaux, M., Certoux, J. M., Contassot, E., Murphy, W. J., Lyons, R., Chiang, Y. and et. al. (1994). Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood, 84: 1333-1341.
69. Traversari, C., Marktel, S., Magnani, Z., Mangia, P., Russo, V., Ciceri, F., Bonini, C. and Bordignon, C. (2007). The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood, 109: 4708-4715.
70. Tuschong, L., Soenen, S. L., Blaese, R. M., Candotti, F. and Muul, L. M. (2002). Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum. Gene Ther., 13: 1605-1610.
71. Verzeletti, S., Bonini, C., Marktel, S., Nobili, N., Ciceri, F., Traversari, C. and Bordignon, C. (1998). Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum. Gene Ther., 9: 2243-2251.
72. Von Laer, D., Hasselmann, S. and Hasselmann, K. (2006). Gene therapy for HIV infection: what does it need to make it work? J. Gene Med., 8: 658-667.
73. Walker, R. E., Carter, C. S., Muul, L., Natarajan, V., Herpin, B. R., Leitman, S. F., Klein, H. G., Mullen, C. A., Metcalf, J. A., Baseler, M., Falloon, J., Davey, R. T., Jr., Kovacs, J. A., Polis, M. A., Masur, H., Blaese, R. M. and Lane, H. C. (1998). Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat. Med., 4: 852-856.
74. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D. and Riddell, S. R. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 333: 1038-1044.
75. Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J. and Muzyczka, N. (1996). A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol., 70: 4646-4654.